Erika Hamilton, Chair, Executive Committee Breast and Breast Program Lead at Sarah Cannon Research Institute, shared a post on LinkedIn:
“Looking forward to Presidential Symposium 1 at ESMO25 later today!
We’ll see pivotal data from DESTINY-Breast 11 and 05, moving T-DXd into the curative setting for HER2+ breast cancer.
These studies will redefine treatment paradigms. Stay tuned to toxicity profiles…important data here.”
You can read also: Breast Cancer Advances at ESMO25 with Erika Hamilton